Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02135445 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT02135445 is a Phase 2 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 103 participants.
The verdict
NCT02135445, a Phase 2 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
Interventions
- DRUG Degarelix
- DRUG TAK-385
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02135445
The ClinicalTrials.gov registry entry for NCT02135445 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT02135445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02135445 about?
NCT02135445 is a clinical study titled "Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer". The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
What is the current status of trial NCT02135445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2014-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02135445?
The interventions under investigation include: Degarelix (DRUG), TAK-385 (DRUG).
Who is sponsoring clinical trial NCT02135445?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.